As of 2025-04-25, the EV/EBITDA ratio of Celldex Therapeutics Inc (CLDX) is -6.56. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLDX's latest enterprise value is 1,258.75 mil USD. CLDX's TTM EBITDA according to its financial statements is -191.90 mil USD. Dividing these 2 quantities gives us the above CLDX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.3x - 12.6x | 11.4x |
| Forward P/E multiples | 19.8x - 20.3x | 20.0x |
| Fair Price | (56.81) - (36.00) | (45.11) |
| Upside | -393.0% - -285.7% | -332.6% |
| Date | EV/EBITDA |
| 2025-04-17 | -6.18 |
| 2025-04-16 | -6.01 |
| 2025-04-15 | -6.21 |
| 2025-04-14 | -6.01 |
| 2025-04-11 | -5.68 |
| 2025-04-10 | -5.37 |
| 2025-04-09 | -5.53 |
| 2025-04-08 | -5.09 |
| 2025-04-07 | -5.29 |
| 2025-04-04 | -5.31 |
| 2025-04-03 | -5.78 |
| 2025-04-02 | -5.86 |
| 2025-04-01 | -5.68 |
| 2025-03-31 | -6.13 |
| 2025-03-28 | -6.75 |
| 2025-03-27 | -6.76 |
| 2025-03-26 | -6.62 |
| 2025-03-25 | -6.82 |
| 2025-03-24 | -7.04 |
| 2025-03-21 | -6.65 |
| 2025-03-20 | -6.73 |
| 2025-03-19 | -6.75 |
| 2025-03-18 | -6.73 |
| 2025-03-17 | -6.89 |
| 2025-03-14 | -6.92 |
| 2025-03-13 | -6.82 |
| 2025-03-12 | -7.18 |
| 2025-03-11 | -6.94 |
| 2025-03-10 | -6.62 |
| 2025-03-07 | -7.00 |
| 2025-03-06 | -7.23 |
| 2025-03-05 | -7.15 |
| 2025-03-04 | -6.77 |
| 2025-03-03 | -6.55 |
| 2025-02-28 | -6.97 |
| 2025-02-27 | -6.88 |
| 2025-02-26 | -6.99 |
| 2025-02-25 | -7.05 |
| 2025-02-24 | -7.23 |
| 2025-02-21 | -7.62 |
| 2025-02-20 | -7.67 |
| 2025-02-19 | -7.83 |
| 2025-02-18 | -7.65 |
| 2025-02-14 | -7.70 |
| 2025-02-13 | -7.83 |
| 2025-02-12 | -7.55 |
| 2025-02-11 | -7.43 |
| 2025-02-10 | -7.30 |
| 2025-02-07 | -7.62 |
| 2025-02-06 | -7.91 |